Formosa Pharmaceuticals, Inc.

As of June 30, 2026, Formosa Pharmaceuticals, Inc. carries a market capitalization of 3.68B, placing it among publicly traded companies globally. Its enterprise value stands at 2.48B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Formosa Pharmaceuticals, Inc. has 150.98M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 69.92, and the price-to-book ratio stands at 2.68.

These figures are as of June 30, 2026. The EV/Sales ratio of 47.25 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.48B versus a market cap of 3.68B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Formosa Pharmaceuticals, Inc. maintains a current ratio of 14.63, meaning it holds 14.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.80, indicating elevated leverage, while an interest coverage ratio of -229.85 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Formosa Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -12.93, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -9.33, reflecting losses generated across the asset base. The company generates approximately 3.29M in revenue per employee across its workforce of 16.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.15 indicates how many times Formosa Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Formosa Pharmaceuticals, Inc. recorded 2.26M in income tax expense. The company reported a pretax loss of -187.71M and -190.05M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Formosa Pharmaceuticals, Inc.'s stock has declined approximately 16.50% over the past 52 weeks. The 50-day moving average sits at 24.18, while the 200-day moving average is 25.92.

Over the twelve months ended June 30, 2026, Formosa Pharmaceuticals, Inc. generated 52.59M in revenue and converted that into -190.05M in net income, yielding earnings per share of -1.26. EBITDA reached -117.68M, while operating income came in at -170.33M.

As of June 30, 2026, Formosa Pharmaceuticals, Inc. holds 1.22B in cash and equivalents against 24.71M in total debt, resulting in a net debt position of -106.75M. Total book value stands at 1.37B, with working capital of 1.29B providing operational flexibility.

Formosa Pharmaceuticals, Inc. produced -287.65M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -7.33M in capital expenditures, free cash flow totaled -294.98M - equivalent to -1.95 per share.

Over the twelve months ended June 30, 2026, Formosa Pharmaceuticals, Inc. posted a gross margin of 57.35, reflecting its pricing power and cost economics. The operating margin of -323.92 and net profit margin of -361.42 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -8.02: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.18, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Formosa Pharmaceuticals, Inc. shareholders.

Formosa Pharmaceuticals, Inc.'s most recent stock split took place on May 24, 2023.

As of June 30, 2026, Formosa Pharmaceuticals, Inc. has an Altman Z-Score of 2.50, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.